What is Palatin?
Palatin Technologies, Inc. is a biopharmaceutical enterprise dedicated to the development of targeted, receptor-specific peptide therapeutics. The company's core competency lies in its melanocortin receptor agonist platform, which addresses a spectrum of conditions including hypoactive sexual desire disorder (HSDD), erectile dysfunction, and various inflammatory diseases. By focusing on precision medicine, Palatin aims to deliver subcutaneous injectable treatments that offer superior efficacy and safety profiles compared to traditional systemic therapies. Beyond its lead programs, the company is actively exploring natriuretic peptide receptor-specific pathways, targeting complex conditions such as heart failure and refractory hypertension. This diversified portfolio positions Palatin as a significant innovator in the life sciences landscape, bridging the gap between preclinical research and late-stage clinical validation.
How much funding has Palatin raised?
Palatin has raised a total of $93.8M across 9 funding rounds:
Other Financing Round
$1.8M
Multiple Rounds
$31.9M
Debt
$10M
Share Placement
$19.8M
Share Placement
$9.2M
Share Placement
$16.5M
Other Financing Round
$4.7M
Other Financing Round (2013): $1.8M with participation from Commercialization Center for Innovative Technologies
Other Financing Round (2014): $1.9M led by Commercialization Center for Innovative Technologies
Share Placement (2014): $20M supported by QVT Financial
Debt (2014): $10M featuring Horizon Technology Finance Corporation
Debt (2015): $10M backed by Horizon Technology Finance Corporation
Share Placement (2015): $19.8M with participation from QVT Financial
Share Placement (2016): $9.2M, investors not publicly disclosed
Share Placement (2016): $16.5M, investors not publicly disclosed
Other Financing Round (2023): $4.7M featuring Commercialization Center for Innovative Technologies
Key Investors in Palatin
QVT Financial
QVT Family Office is composed of a diverse group of original thinkers with non-traditional backgrounds, offering unique expertise in smart investment strategies. The firm focuses on various core areas including biotech, technology, energy, financials, and opportunistic investments.
Horizon Technology Finance Corporation
Horizon Technology Finance is a specialty finance company that operates within the broader financial services sector, focusing on providing structured debt financing solutions to development-stage companies in the life sciences and technology sectors.
Commercialization Center for Innovative Technologies
An investment entity focused on supporting the commercialization of innovative technologies and early-stage research initiatives within the life sciences and biotechnology industries.
What's next for Palatin?
With the recent infusion of $4.7M, Palatin is strategically positioned to accelerate its Phase III clinical studies and expand its preclinical pipeline. The company's forward-looking strategy emphasizes the commercialization of its lead assets while simultaneously de-risking its early-stage programs through rigorous clinical data generation. Investors are closely monitoring the firm's ability to navigate regulatory hurdles and achieve key milestones in its melanocortin and natriuretic receptor programs. As Palatin continues to refine its therapeutic focus, the integration of strategic capital will be pivotal in sustaining its competitive advantage in the highly specialized peptide therapeutics market. The firm's long-term objective remains the delivery of transformative treatments that address significant gaps in current medical standards, ultimately driving value for stakeholders through clinical success and potential commercial partnerships.
See full Palatin company page
